Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance

Mesoblast LimitedTrade
ZIM Integrated Shipping Services LtdTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs ZIM Integrated Shipping Services Ltd — how do they compare? Mesoblast Limited trades at $16.86 (market cap $2.21B), while ZIM Integrated Shipping Services Ltd trades at $25.29 (market cap $2.96B). The key difference: ZIM Integrated Shipping Services Ltd is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOZIM
Market Cap
$2.21B$2.96B
Sector
TechnologyIndustrials
52-Week High
$20.96$29.27
52-Week Low
$12.88$12.44
Enterprise Value
$2.21B$6.81B
Dividend Yield
20.16%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

ZIM Integrated Shipping Services Ltd

ZIM trades at $25.29, up 0.32% on the day, amid a bearish technical outlook and mixed earnings performance. The stock shows weak profitability with a net margin of 1.56% and declining revenue projections for 2026. Recent news highlights uncertainty around a potential merger with Hapag-Lloyd and upcoming Q2 2026 earnings, with analyst sentiment evenly split between hold and sell recommendations.

The outlook for ZIM is cautious, with risks from merger uncertainty and operational pressures outweighing its low valuation multiples. Investment opportunity hinges on successful execution and merger approval, but current fundamentals and bearish technicals suggest limited near-term upside amid high volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About ZIM Integrated Shipping Services Ltd

ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.

Read more on ZIM